Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- (Part 1 – M0324 alone) People with certain advanced or spreading solid tumours that produce high levels of a protein called MUC-1, where standard treatments have stopped working, caused intolerable side effects, or where the treating doctor considers no standard treatment to be appropriate.
- (Part 2 – M0324 combined with pembrolizumab) People with certain advanced or spreading tumours that produce high levels of MUC-1, who have already received a type of cancer treatment called immune checkpoint inhibitors, whose disease continued to grow or spread during or after that treatment, and where the treating doctor considers no further standard treatment to be appropriate.
- (Part 3 – M0324 combined with mFOLFIRINOX) People with pancreatic cancer that has spread to other parts of the body and has not yet been treated, where the treating doctor considers a chemotherapy regimen called mFOLFIRINOX to be appropriate.
- Additional criteria set by the trial protocol may also apply (confirm with trial site).
Who may not be able to join:
- People with a history of ongoing or severe diarrhoea, inflammatory bowel disease affecting the colon or rectum, or a bowel blockage that has not fully resolved.
- People who have had another cancer diagnosed within the past 3 years before enrolling in the trial.
- People with heart or blood pressure conditions that are not well controlled, including uncontrolled high blood pressure, irregular heartbeat, unstable chest pain, a recent heart attack, moderate-to-severe heart failure, or a heart procedure performed within the last 180 days.
- People whose life expectancy is estimated to be less than 3 months.
- People who have previously had a Whipple surgical procedure or chemotherapy given after surgery (adjuvant chemotherapy) are not eligible for Part 3 of the trial.
- Additional exclusion criteria set by the trial protocol may also apply (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Responsible, EMD Serono Research & Development Institute, Inc.
Phone: 888-275-7376
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Parts 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs); Part 1, 2 and 3: Number of Participants with Treatment-Emergent Adverse Events (TEAEs); Part 3: Number of Participants With Dose Limiting Toxicities (DLTs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.